Clinical and prognostic role of annexin A2 in multiple myeloma

Blood

Volumn 120, Issue 5, 2012, Pages 1087-1094

  Seckinger, Anja ^a,b   Meißner, Tobias ^a   Moreaux, Jérôme ^c,d   Depeweg, Daniela ^a   Hillengass, Jens ^a   Hose, Katja ^a,e   Rème, Thierry ^c,d   Rösen Wolff, Angela ^f   Jauch, Anna ^g   Schnettler, Reinhard ^e   Ewerbeck, Volker ^a   Goldschmidt, Hartmut ^a,b   Klein, Bernard ^c,d   Hose, Dirk ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Nationales Centrum fur Tumorerkrankungen   (Germany)

^c HÔPITAL SAINT ELOI   (France)

^d INSERM   (France)

^e UNIVERSITY HOSPITAL GIESSEN   (Germany)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; LIPOCORTIN 2; MELPHALAN; SYNDECAN 1;

ANXA2 GENE; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE REMODELING; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL POPULATION; CELL PROLIFERATION; CHROMOSOME ABERRATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOMA CELL; NUCLEOTIDE SEQUENCE; ONCOGENE; OSTEOBLAST; OSTEOCLAST; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL; TUMOR MICROENVIRONMENT;

EID: 84864530705     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-415588     Document Type: Article

References (50)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860-1873.
2. Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006;135(2):158-164. (Pubitemid 44401612)
3. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940-948.
4. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64(4):1546-1558. (Pubitemid 38235629)
5. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489-3495. (Pubitemid 46572539)
6. Hose D, Moreaux J, Meissner T, et al. Induction of angiogenesis by normal and malignant plasma cells. Blood. 2009;114(1):128-143.
7. Hose D, Rème T, Meissner T, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood. 2009;113(18):4331-4340.
8. Seckinger A, Meissner T, Moreaux J, et al. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene. 2009;28(44):3866-3879.
9. Caers J, Hose D, Kuipers I, et al. Thymosin beta4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. Haematologica. 2010;95(1):163-167.
10. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-2028. (Pubitemid 44395016)
11. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26):6333-6338. (Pubitemid 46218843)
12. Mahtouk K, Hose D, Raynaud P, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood. 2007;109(11):4914-4923. (Pubitemid 46827789)
13. Mahtouk K, Hose D, Rème T, et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene. 2005;24(21):3512-3524. (Pubitemid 40756252)
14. Klein B, Seckinger A, Moehler T, Hose D. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment. Recent Results Cancer Res. 2011;183:39-86.
15. Munshi NC, Hideshima T, Carrasco D, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004;103(5):1799-1806. (Pubitemid 38268976)
16. Bao H, Jiang M, Zhu M, Sheng F, Ruan J, Ruan C. Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol. 2009;90(2):177-185.
17. Lu G, Maeda H, Reddy SV, et al. Cloning and characterization of the annexin II receptor on human marrow stromal cells. J Biol Chem. 2006;281(41):30542-30550. (Pubitemid 44582110)
18. D'Souza S, Kurihara N, Shiozawa Y, et al. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood. 2012;119(8):1888-1896.
19. Sharma MC, Sharma M. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des. 2007;13(35):3568-3575. (Pubitemid 350238927)
20. Ling Q, Jacovina AT, Deora A, et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest. 2004;113(1):38-48. (Pubitemid 38541630)
21. Gillette JM, Nielsen-Preiss SM. The role of annexin 2 in osteoblastic mineralization. J Cell Sci. 2004;117(3):441-449. (Pubitemid 38181205)
22. Menaa C, Devlin RD, Reddy SV, Gazitt Y, Choi SJ, Roodman GD. Annexin II increases osteoclast formation by stimulating the proliferation of osteoclast precursors in human marrow cultures. J Clin Invest. 1999;103(11):1605-1613.
23. Takahashi S, Reddy SV, Chirgwin JM, et al. Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption. J Biol Chem. 1994;269(46):28696-28701. (Pubitemid 24366705)
24. Li F, Chung H, Reddy SV, et al. Annexin II stimulates RANKL expression through MAPK. J Bone Miner Res. 2005;20(7):1161-1167. (Pubitemid 40863803)
25. Decaux O, Lodé L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2008;26(29):4798-4805.
26. Shaughnessy JD, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-2284. (Pubitemid 46425864)
27. Hose D, Reme T, Hielscher T, et al. Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. Haematologica. 2011;96:87-95.
28. Greipp PR, Miguel JS, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-3420.
29. Durie BG. Staging and kinetics of multiple myeloma. Semin Oncol. 1986;13(3):300-309. (Pubitemid 17204708)
30. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115-1123. (Pubitemid 28435189)
31. Barlogie B, Tricot G, Rasmussen E, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006;107(7):2633-2638.
32. van Rhee F, Szymonifka J, Anaissie E, et al. Total therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide and dexamethasone, relevant to all phases of therapy. Blood. 2010;116:1220-1227.
33. Moreaux J, Cremer FW, Reme T, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood. 2005;106(3):1021-1030. (Pubitemid 41076449)
34. Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994;83(12):3654-3663. (Pubitemid 24175556)
35. Corre J, Mahtouk K, Attal M, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 2007;21(5):1079-1088. (Pubitemid 46672085)
36. Fuhler GM, Baanstra M, Chesik D, et al. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res. 2010;316(11):1816-1828.
37. Wagner W, Wein F, Seckinger A, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol. 2005;33(11):1402-1416. (Pubitemid 41541969)
38. Wuilleme S, Robillard N, Lodé L, et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia. 2005;19(2):275-278. (Pubitemid 40220593)
39. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F. A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc. 2004;99:909-917. (Pubitemid 39665934)
40. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118-127. (Pubitemid 44906106)
41. Warren P, Taylor D, Martini PGV, Jackson J, Bienkowska J. PANP-a new method of gene detection on oligonucleotide expression arrays. 2007 BIBE 2007 Proceedings of the 7th IEEE International Conference on Bioinformatics and Bioengineering. 2007;108-115.
42. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
43. Benjamini Y, Hochberg Y. Controlling the false discovery: a practical and powerful approach to multiple testing. J R Stat Soc Series B. 1995;57:289-300.
44. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
45. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349(26):2483-2494. (Pubitemid 38010074)
46. Sprynski AC, Hose D, Caillot L, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 2009;113(19):4614-4626.
47. Esposito I, Penzel R, Chaib-Harrireche M, et al. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol. 2006;208(5):673-685.
48. Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol. 2006;81(2):146-156. (Pubitemid 44715786)
49. Liu J-W, Shen J-J, Tanzillo-Swarts A, et al. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene. 2003;22(10):1475-1485. (Pubitemid 36390596)
50. Shiozawa Y, Havens AM, Jung Y, et al. Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem. 2008;105(2):370-380.